Method for treating a immunology-related disease
A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is unsubstituted C 3 -C 10 cycloalkyl, unsubstituted C 3 -C 10 aryl, or C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.
1. A method for the treatment of an immunology-related disease selected from the group consisting of systemic lupus erythematosus, polymyositis, fibrositis, skeletal muscle inflammation, arthrosteitis, osteoarthritis, dermatomyositis, scleoderma, Behcet's syndrome, autoimmune hepatitis, aplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune bullosis, psoriasis vulgaris, vasculitis syndrome, Wegener's granuloma, uveitis, Sjögren's syndrome, idiopathic interstitial pneumonia, Goodpasture's syndrome, sarcoidosis, allergic granulomatous angitis, bronchial asthma, myocarditis, cardiomyopathy, aortitis syndrome, post myocardial infarction syndrome, primary pulmonary hypertension, minimal change nephrotic syndrome, membranous nephropathy, membranoproliferative glomerulonephritis, focal glomerular sclerosis, crescentic glomerulonephritis, myasthenia gravis, inflammatory neuropathy, chronic actinic dermatitis, photosensitivity, pressure sores, Sydenham's chorea, sclerosis, adult-onset type diabetes mellitus, juvenile diabetes mellitus, atherosclerosis, IgA nephropathy, tubulointerstitial nephritis, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant hepatitis, viral hepatitis, GVHD, contact dermatitis, sepsis, an infection caused by fungus, mycoplasma, virus or protozoan, cardiac failure, cardiac hypertrophy, arrhythmia, angina pectoris, cardiac ischemia, arterial embolism, aneurysm, varix, a circulation disorder, Alzheimer's disease, dementia, Parkinson's disease, stroke, brain infarction, brain ischemia, depression, manic-depressive illness, schizophrenia, Huntington's chorea, epilepsy, convulsion, attention deficit disorder, encephalitis, cerebral meningitis, loss of appetite, hyperphagia, lymphoma, leukemia, diuresis, pollakisuria and diabetic retinopathy in a mammal in need thereof, which comprises administering to said mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia):
wherein R 1 and R 2 are each a hydrogen atom;
R 3 is a hydrogen atom;
R 4 is a C 1 -C 2 alkyl group;
n is 2;
X is ═N-D, wherein D is a hydrogen atom, a C 1 -C 4 alkyl group or a phenyl group;
Y is an ethylene group, an ethynylene group, a group of a formula —CO—CH 2 or a phenylene group;
Z is an ethylene group or a trimethylene group;
R 5 is an unsubstituted C 3 -C 10 cycloalkyl group, an unsubstituted C 6 -C 10 aryl group, or a C 3 -C 10 cycloalkyl group or a C 6 -C 10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group and a lower alkoxy group; and
R 6 and R 7 are each a hydrogen atom.
2. The method according to claim 1 , wherein the mammal is a human.
3. The method according to claim 2 , wherein, in the compound, R 4 is a methyl group, or a pharmacologically acceptable salt thereof.
4. The method according to claim 3 or a pharmacologically acceptable salt thereof, wherein, in the compound, X is a group of a formula ═N—CH 3 , or a pharmacologically acceptable salt thereof.
5. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
6. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
7. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
8. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.
9. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.
10. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.
11. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
12. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
13. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
14. The method according to claim 2 , wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
15. The method according to claim 2 , wherein R 1 , R 2 and R 3 are each a hydrogen atom, R 4 is a methyl group, n is 2 and Y—Z—R 5 is —(O—(CH 2 ) 3 -(4-F-phenyl).
16. The method according to claim 5 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
17. The method according to claim 6 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
18. The method according to claim 7 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
19. The method according to claim 8 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
20. The method according to claim 9 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
21. The method according to claim 10 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
22. The method according to claim 11 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
23. The method according to claim 12 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
24. The method according to claim 13 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
25. The method according to claim 14 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
26. The method according to claim 15 , wherein the configuration at the carbon atom to which the group of the formula —NR 1 R 2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.